Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’ve got a lot of big news today — from a major move by a PBM to a C-suite shakeup. Read on for more.
In a first, FDA allows a ‘psychedelic without the trip’ to be tested at home
Delix Therapeutics, which is developing a psychedelic-like drug for depression, reported promising early data this morning and said that for its next trial, the FDA will allow patients to take the drug — designed to not be hallucinogenic — at home.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply